Table of Contents
ISRN Addiction
Volume 2014 (2014), Article ID 927290, 7 pages
http://dx.doi.org/10.1155/2014/927290
Clinical Study

Pharmacodynamics Must Inform Statistics: An Example from a Cocaine Dependence Pharmacotherapy Trial

1Addiction Sciences Division, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, College of Medicine, 3131 Harvey Avenue, Cincinnati, OH 45229, USA
2Veterans Affairs Medical Center (VISN 10), 3200 Vine Street, Cincinnati, OH 45220, USA
3Department of Mathematical Sciences, University of Cincinnati, 2693 Campus Drive, Cincinnati, OH 45221, USA
4Division of Neurology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue Cincinnati, OH 45229, USA

Received 21 November 2013; Accepted 22 December 2013; Published 5 February 2014

Academic Editors: A. M. Barr, J. Krejci, and C. L. Paul

Copyright © 2014 Theresa M. Winhusen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. J. Vocci, J. Acri, and A. Elkashef, “Medication development for addictive disorders: the state of the science,” American Journal of Psychiatry, vol. 162, no. 8, pp. 1432–1440, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. S.-Y. Kang, P. H. Kleinman, G. E. Woody et al., “Outcomes for cocaine abusers after once-a-week psychosocial therapy,” American Journal of Psychiatry, vol. 148, no. 5, pp. 630–635, 1991. View at Google Scholar · View at Scopus
  3. K. M. Carroll, B. J. Rounsaville, C. Nich, L. T. Gordon, P. W. Wirtz, and F. H. Gawin, “One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence: delayed emergence of psychotherapy effects,” Archives of General Psychiatry, vol. 51, no. 12, pp. 989–997, 1994. View at Google Scholar · View at Scopus
  4. O. Aalen, “Medical statistics—no time for complacency,” Statistical Methods in Medical Research, vol. 9, no. 1, pp. 31–40, 2000. View at Google Scholar · View at Scopus
  5. T. Winhusen, E. Somoza, O. Sarid-Segal et al., “A double-blind, placebo-controlled trial of reserpine for the treatment of cocaine dependence,” Drug and Alcohol Dependence, vol. 91, no. 2-3, pp. 205–212, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. A. A. Baumeister, M. F. Hawkins, and S. M. Uzelac, “The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis,” Journal of the History of the Neurosciences, vol. 12, no. 2, pp. 207–220, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Berger, T. Winhusen, E. Somoza et al., “A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence,” Addiction, vol. 100, supplement s1, pp. 58–67, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. M. B. First, R. L. Spitzer, M. Gibbon, and J. B. W. Williams, Structured Clinical IntervieW of Axis I DSM-IV Disorders—Patient Edition (With Psychotic Screen) (SCID-I/P W/ Psychotic Screen, Version 2.0), New York State Psychiatric Institute, New York, NY, USA, 1996.
  9. H. Abdi, “Bonferroni and Sidak corrections for multiple comparisons,” in Encyclopedia of Measurement and Statistics, N. J. Salkind, Ed., Sage, Thousand Oaks, Calif, USA, 2007. View at Google Scholar
  10. A. Carlsson, “Monoamine-depleting drugs,” Pharmacology and Therapeutics B, vol. 1, no. 3, pp. 393–400, 1975. View at Google Scholar · View at Scopus
  11. K.-Y. Liang and S. L. Zeger, “Longitudinal data analysis using generalized linear models,” Biometrika, vol. 73, no. 1, pp. 13–22, 1986. View at Publisher · View at Google Scholar · View at Scopus
  12. S. L. Zeger, K.-Y. Liang, and P. S. Albert, “Models for longitudinal data: a generalized estimating equation approach,” Biometrics, vol. 44, no. 4, pp. 1049–1060, 1988. View at Google Scholar · View at Scopus
  13. A. V. Chobanian, G. L. Bakris, H. R. Black et al., “The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report,” The Journal of the American Medical Association, vol. 289, no. 19, pp. 2560–2572, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Collins, R. Peto, S. MacMahon et al., “Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context,” The Lancet, vol. 335, no. 8693, pp. 827–838, 1990. View at Publisher · View at Google Scholar · View at Scopus